Skip to content

Feasibility study of circulating tumor cells (CTC) and their HIF-1a mRNA expression levels in evaluating the efficacy of downstaging and conversion therapy and monitoring of postoperative recurrence risk in middle-advanced primary liver cance

Feasibility study of circulating tumor cells (CTC) and their HIF-1a mRNA expression levels in evaluating the efficacy of downstaging and conversion therapy and monitoring of postoperative recurrence risk in middle-advanced primary liver cance

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058559
Enrollment
Unknown
Registered
2022-04-11
Start date
2022-04-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Group 1:targeted drugs
Group 3:infusion chemotherapy
Group 4:chemoembolization

Sponsors

Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 70 years, ECOG (physical condition) score 0-2; 2. Clinical diagnostic criteria for liver cancer were met before surgery according to the 2018 Guidelines for Diagnosis and Treatment of Liver Cancer in China; All patients were evaluated as inoperable; 3. All patients received conversion therapy for liver cancer; 4. No other anti-tumor therapy, such as radiotherapy and chemotherapy, biotherapy and local ablation, was performed before treatment; 5. The patient was free of AIDS, other malignant tumors, heart disease and other basic diseases before surgery; 6. Voluntarily attend and regularly accept follow-up examinations.

Exclusion criteria

Exclusion criteria: 1. Severe complications of heart, lung, kidney and other important organs such as dyspnea and heart failure occurred during the observation period; 2. During the observation period, patients received liver surgery, local ablation, radiotherapy, biotherapy and other treatments; 3. The patient developed malignant tumors of other organs during the observation period; 4. Insufficient blood supply to the tumor; 5. Patients with widely spread metastatic tumors, whose survival time is less than 3 months; 6. Liver function: Child -- Pugh grade C; 7. The patient was not willing to continue the study within 1 year.

Design outcomes

Primary

MeasureTime frame
Circulating tumor cell;Tumor imaging data;Objective remission rate;

Secondary

MeasureTime frame
Progression-free survival;Overall survival;

Countries

China

Contacts

Public ContactZhang Yu

Sichuan Provincial People's Hospital

68532815@qq.com+86 18981838352

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026